Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PCNA”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 253 records · Page 14Linked to original sources

Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL).

Chronic Lymphocytic Leukemia (CLL) is usually an indolent disorder which in some patients assumes an aggressive clinical course. In order to assess at presentation the prognosis of a given patient, several staging systems and prognostic variables have been proposed including the expression of the Proliferating Cell Nuclear Antigen (PCNA). PCNA is a 36 kd nuclear protein, the regulation of which is cell cycle-dependent. In CLL, PCNA levels correlate with cell proliferation, clinical stage and the lymphocyte doubling time (LDT). Furthermore, preliminary data suggests that PCNA expression may also predict response to Fludarabine-based chemotherapy. Since PCNA is a cofactor for Delta DNA polymerase, PCNA overexpression in CLL may also reflect the intrinsic DNA repair activity of the leukemic cells and thus their resistance to chemotherapy. Further studies aiming at modulation of PCNA expression in CLL cells may clarify this issue and may offer a future new therapeutic strategy with which to treat this disorder.

Antigens, Neoplasm↗

Prognostic implications of proliferating cell nuclear antigen (PCNA), AgNORs and P53 in non-Hodgkin's lymphomas.

We investigated the prognostic value of proliferating cell nuclear antigen (PCNA) and p53 oncoprotein expression and of nucleolar organiser region (NOR) scoring, in relation to classic clinicopathological parameters, in a series of non-Hodgkin's lymphomas (NHL). Paraffin embedded tissue from 91 patients with NHL was stained immunohistochemically with the monoclonal antibodies PC-10 (PCNA) and DO-1 (p53) and histochemically with the AgNOR technique. The median follow-up was 48 (4 to 193) months. The impact of PCNA and p53 expression and of AgNOR number on survival was tested using univariate as well as multivariate analysis, in order to circumvent the heterogeneity in histologic grade, type and therapy. Univariate analysis identified seven variables related to overall survival: histologic type and grade, clinical stage, chemotherapy, p53 labelling index (LI), PCNA LI and AgNOR score, whereas only one parameter i.e. histologic grade influenced disease-free survival. In multivariate analysis stage, PCNA LI and AgNOR score predicted independently overall survival. PCNA was also the only independent predictor of post-relapse survival and histologic grade the most important indicator of disease-free survival. In conclusion, PCNA expression and AgNOR number may be better predictors of overall and post-relapse survival than histologic grade. The latter remains the most valuable prognostic indicator of disease-free survival.

Adolescent↗

Comparison of brain tumor growth kinetics by proliferating cell nuclear antigen (PCNA) and bromodeoxyuridine (BrdU) labeling.

The bromodeoxyuridine (BrdU) labeling study provides valuable cell kinetic information for individual tumors that could suggest the prognosis of each patient who had a tumor. Recently, a monoclonal antibody against the proliferating cell nuclear antigen (PCNA or cyclin), a nuclear protein expressed in proliferating cells, was developed which could be used on formalin fixed, paraffin embedded tissue. The purpose of this study was to compare the cell kinetic data obtained by the BrdU labeling study and the PCNA method in the same patient. The relationship between labeling indices of BrdU incorporated into S-phase and PCNA expressed by cycling cells was investigated in 31 patients with brain tumors. Both of the labeling indices showed good correlation with histological grade of the tumor. The values of the PCNA labeling index (LI) were parallel but higher than those of the BrdU LI, and the relation PCNA LI = 2.2 x BrdU LI + 0.8 (r2 = 0.86) was obtained. The results of this study show that PCNA could replace the BrdU method for identifying the proliferating cells, and the major advantages of PCNA method is that it could be done without any pretreatment and avoid injection of the teratogenic agent for diagnostic purpose.

Adolescent↗

p53 and PCNA expression in benign, atypical and malignant meningiomas.

OBJECTIVE: Alterations: p53 genes are turning out to be the most common genetic alterations in human cancers. Due to long half-life of mutated p53, its detection is possible by immunohistochemistry. Proliferating cell nuclear antigen (PCNA) is expressed by dividing cells, hence has been shown to correlate with prognosis. We have used monoclonal antibodies protein DO-7 (p53) and PC10 (PCNA) to see whether their expression correlates with histological grading in meningethelial tumour. MATERIAL AND METHODS: Twenty nine meningiomas (20 benign, 7 atypical and 2 malignant) were selected from the records of our laboratory. p53 and PCNA expression was sought by immunohistochemistry using Peroxidase Anti Peroxidase (PAP) technique. RESULTS: Four benign and 2 atypical meningiomas showed weak staining for p53. Both malignant meningiomas showed strong positivity for p53. Six benign meningiomas had less than 5% PCNA positivity, one 10% positivity and three showed 20% positivity. PCNA positivity ranged for 10-80% in atypical meningiomas. In two malignant meningiomas PCNA positivity was 70% and 90%. CONCLUSION: It is worthwhile to include p53 and PCNA expression along with histologic assessment in predicting outcome of meningiomas. A larger series with complete follow-up is essential in assessing value of these markers which unfortunately remains a dream in our country.

Humans↗

Immunohistochemical staining properties of PCNA, Ki-67, p53, beta-hCG and HPL in trophoblastic disease.

OBJECTIVE: In this study proliferating markers PCNA (proliferating cell nuclear antigen) Ki-67 and mutation of supressor gene p53 were investigated in gestational trophoblastic disease (GTL). These markers were tested by using immunostaining with beta subunits of human chorionic gonadotropin (hCG) and human placental lactogen (HPL). MATERIAL AND METHODS: Twenty curetting samples, 20 spontaneous abortions, 16 hydatidiform moles and two choriocarcinomas were studied and compared. Hydatidiform moles were subdivided into 10 complete and six partial moles by using flow cytometry analysis. All slides were stained with PCNA, Ki-67, p53, hCG, and HPL immunohistochemically. PCNA and Ki-67 stained slides were studied quantitatively to determine the PCNA and Ki-67 index. Other slides that were stained with p53, hCG, HPL were evaluated according to staining percentage and intensity. Staining properties of all groups were compared with each other. Variance analysis and the Mann Whitney U test were used for statistical analysis. Choriocarcinomas were not included in the statistical analysis. Ki-67 and the PCNA index in two choriocarcinoma cases found 81.4% and 41%, and 44% and 64%, respectively. One case was stained in 70% with (++) intensity by p53. While both were stained in 80% with (++) intensity by hCG, one was stained in 30% field (+) intensity by HPL. RESULTS: The four groups of complete and incomplete diagnosed hydatiform moles, spontaneous abortions and retention curettage were matched in pairs and evaluated according to the PCNA index. This index showed significant differences among the groups. The differences among the Ki-67 index, p53, hCG and HPL staining properties were not statistically significant. CONCLUSION: Our findings showed that PCNA is a significant and useful marker for trophoblastic diseases and can be used as a prognostic factor.

Adult↗

Expression of p21 in non small cell lung cancer relationship with PCNA.

The first cyclin dependent kinase inhibitor to be discovered was the p21 cdk interacting protein (a.k.a., WAF1, Cip1, CAP20, Sdi1, mda6). p21 expression may or may not be dependent on p53. This pathway also inhibits DNA replication by merit of p21's interaction with PCNA, but it has also been shown that this same inhibitory interaction with p21 does not affect PCNA DNA repair abilities. We assessed the immunohistochemical expression of p21 protein in 60 curative surgical resected non small cell lung cancers relating it to the expression of PCNA to clarify the contribution of the p21/PCNA pathway to the development of NSCLC. We did not find any relationship between PCNA and p21 expression. This last result may indicate that the mechanism by which PCNA controls the DNA repair is the most important activity of this protein during lung cancer progression and development, compared to its contribution to cell proliferation. In fact, this last event is strongly counteracted by p21 expression, which in this last case works as an inhibitor of PCNA expression. In conclusion this study highlighted the important role of the p21/PCNA pathway in lung carcinogenesis, pointing out the contribution of PCNA to the response to lung aggression and not only it's role as a proliferation index. Therefore, these results offer a background to further study to evaluate potential novel therapeutic approaches to lung cancer treatment.

Adenocarcinoma↗

[Assessment of usefulness of PCNA and oncoprotein p53 staining in prediction of the recurrences in subjects operated on for laryngeal carcinoma].

The authors estimated PCNA and P53 in subjects with laryngeal cancer with local or nodal recurrences. The study concerned 54 patients from Upper Silesia aged 37-79 (mean 57 +/- 8.8). The mean value of the PCNA index in subjects with local recurrence (LR) was 24.2% +/- 12.1 while in subjects without LR 22.1% +/- 9.4 (p > 0.05). Additionally, 21 subjects in whom no lymph node metastases were found during laryngectomy were separated from the investigated group. In 16 of them local recurrences were observed and the mean value of PCNA index was 30.9% +/- 12.5. In remaining 5 subjects in whom local recurrences were not developed the mean value of PCNA index was 21.7% +/- 11.2. The analysis of the P53 index in subjects with LR revealed significantly higher values (19.2% +/- 9.1) in comparison with cases without LR (13.2% +/- 6.3). The assessment of the mean values of PCNA and P53 index depending on T, N or stage as well as nodal recurrence did not reveal any statistical significance. Our study revealed usefulness of the P53 and PCNA as markers which could support the histological diagnostic process describing biology of the cancer cells. The demonstrated increase of PCNA and P53 index in patients with LR might be useful in prediction of LR.

Adult↗

The role of different biomarkers (DNA, PCNA, apoptosis and karyotype) in prognostic evaluation of superficial transitional cell bladder carcinoma.

BACKGROUND: In order to clarify the variable behaviour of transitional cell bladder carcinomas (TCBC) with same clinico-pathologic pattern, we investigated the prognostic significance of various biomarkers (PCNA, DNA, apoptosis, karyotype). MATERIALS AND METHODS: We studied 177 superficial TCBC (stage T1) undergoing transurethral resection (TUR). Analysis of biological indicators was performed on serial paraffin sections: DNA by static cytometry, karyotype by fluorescence in situ hybridisation (FISH), PCNA and apoptosis by immunohistochemistry. RESULTS: The most salient results are represented by prevalence of diploidy (56%), a mean PCNA labeling index (PCNA-LI) of 8.2%, nonrandom trisomies and tetrasomies of chromosome 7, and a high presence of apoptosis (in 72% of cases). These data were not related to histological grading. Multivariate analysis showed that only PCNA-LI is a an independent prognostic marker for patient survival (p = 0.01). Besides, we observed a worse prognosis in the presence of both very high PCNA indices and low or absent apoptosis. CONCLUSIONS: The results of this study suggest that tumor prognostic potential in TCBC should be evaluated on the basis of the association between PCNA cell kinetics and cell apoptosis information.

Aged↗

PCNA and P53 expression in relation to clinicopathological features of oral papilloma.

Although papilloma is the most frequent benign epithelial tumour of oral cavity, its biological potential for malignant transformation is still to be evaluated. The aim of the study was to correlate PCNA and P53 expression in 55 oral papillomas with some clinicopathological variables. The tissue samples were stained with H+E and by immunohistochemistry for PCNA and P53 protein. Staining patterns were assessed semiquantitatively and correlated with each other and grade of tumour epithelial dysplasia, tumour size, localization well patient age and sex. PCNA immunostaining was positive 43 (78%) oral papillomas. P53 immunohistochemical reaction was positive in 38 (69%) out of 55 epithelial tumours. Positive relationship between PCNA and P53 expression was observed as well as between PCNA immunostaining and grade of epithelial dysplasia. There was no statistically significant relationships between PCNA, P53 immunohistochemical positivity and papilloma size, site, patient age and sex. The results of this study suggest that immunohistochemical P53 overexpression is valuable marker of early neoplastic transformation and together with PCNA are presumed predictors for malignant transformation of oral papillomas.

Adult↗

[Effect of protein expression on antisense c-myc and PCNA for vascular smooth muscle cells].

OBJECTIVE: To study the methods of inhibiting proliferation of vascular smooth muscle cells (VSMCs), we observed the change of protein expression after using antisense c-myc, PCNA for VSMCs. METHODS: The sense, antisense, and mismatched oligomers for c-myc or PCNA were individually delivered to the cultured VSMCs. Using Western blot, immunohistochemistry assay and image analysis system, we observed the change of c-myc and PCNA protein expression in the VSMCs. RESULTS: Antisense c-myc, PCNA at concentration of 10 micromol/L can successfully inhibit the expression of c-myc, PCNA protein in the VSMCs (P < 0.05), but the sense and the mismatched do not have this effect (P > 0.05). CONCLUSION: The data suggested that the antisense c-myc, PCNA could attenuate the protein expression of c-myc, PCNA, and it is an effective method for the inhibition of VSMCs hyperplasia.

Blotting, Western↗

[Effect of PCNA antisense oligooxynucleotides and VEGF antisense oligoxynucleotides on growth of hepatocellular carcinoma transplanted in nude mice].

OBJECTIVE: To study the inhibitory effect of PCNA antisense oligonucleotides or/and VEGF antisense oligonucleotides on growth of human hepatocellular carcinoma in nude mice. METHODS: Human hepatocellular carcinoma transplanted subcutaneously in nude mice model was established, and subsequently was divided into four groups: PCNA-ASODN group, VEGF-ASODN group, combined group and control group. Different treatments were given respectively. The weigh and volume of subcutaneous tumors was measured, and the morphological changes of tumor cells was observed under microscope. RESULTS: The growth inhibitory rate in the PCNA-ASODN group was 72.8%, 44.9% in the VEGF-ASODN group, and 87.2% in the combined group. The combined group which was treated with PCNA-ASODN and VEGF-ASODN showed more effective inhibitory than the PCNA-ASODN group or the VEGF-ASODN group respectively. CONCLUSIONS: The growth of human hepatocellular carcinoma in nude mice can be inhibited by PCNA antisense oligonucleotides and VEGF antisense oligonucleotides respectively. Better inhibitory effect can be obtained if PCNA antisense oligonucleotides and VEGF antisense oligonucleotides are combined in use.

Animals↗

[The expression of PCNA and NOR in carcinogenesis procession of hamster buccal pouch mucosa].

OBJECTIVE: To investigate the expression of proliferating cell nuclear antigen (PCNA) and nucleolar organizer regions (NOR) with the carcinogenesis model of hamster buccal pouch mucosa. METHODS: 48 Syrain hamsters with 6-8 weeks old and 70-80 g weight were selected. The material used for inducing cancer is 0.5% DMBA (7,12-dimethylbenzanthracene) in acetone. 0.5% DMBA was applied in the right buccal pouch of the hamster 3 times a week for 12 weeks. The control received no treatment. The time for collecting specimens was 3, 6, 9 and 12 weeks. The specimens were immediately fixed with 10% formalin, dyed with HE, and then two doctors major in histopathology evaluated with the WHO criterion (1986). The wax of immunohistochemical specimen was cut and placed on the APES pieces of glass, treated with 50 degrees C for 2 hours and preserved under the indoor temperature. The PCNA was examined with the LSAB technique of immunohistochemistry. The company called Zymed provided the MonAb. The positive control was a sample of human inflammatory hyperplastic lymphoma, and the negative was PBS replacing the MonAb. NOR count was determined in a method of silver nitrate staining. The test condition should be at 45 degrees C without light. RESULTS: 1. AgNOR was usually located in the basal-cell layer of normal epithelium, mainly in a single form. High dysplasia was mainly in an aggregated form, however, carcinoma in infiltration appeared to be in a mixed form. 2. PCNA expression was similar to that of the normal control in hyperplastic epithelia (3 weeks) at a moderate level in dysplasia epithelia (6-9 weeks). PCNA expressed highly in squamous cell carcinoma. The expression of the PCNA in line with malignant progress became stronger increasingly. The positive cell was perceivable in all epithelia of high dysplasia. CONCLUSION: PCNA has been significantly positive and correlative with AgNOR (r = 0.635, P < 0.001), however, the film of PCNA is much clearer and the practical value is greater.

Animals↗

The expression of proliferating cell nuclear antigen (PCNA) and of nucleolar organizer regions (AgNORs) correlates with the morphological type of bone marrow plasma cells in multiple myeloma (MM).

UNLABELLED: Proliferating cell nuclear antigen (PCNA) is a DNA polymerase delta accessory protein, and is an indicator of the proliferative state of the cell. Nucleolar organizer regions (NORs) are loops of DNA that carry the ribosomal RNA (rRNA) genes and are markers of aggressiveness for certain tumors. PATIENTS AND METHODS: This study tested the correlation between plasma cell morphology and PCNA and NOR expression in 50 multiple myeloma (MM) patients prior to therapy. 50 MM bone marrow trephine biopsies were studied using the monoclonal antibody PC-10 and the colloid silver nitrate method for identification of PCNA and AgNors, respectively. RESULTS: PCNA positive cells ranged from 2% to 100%, higher PCNA expression was observed in patients with immature type of MM (mean 29.5%, SD = 5.5), the highest expression was seen in plasmablastic type MM (mean 60.5%, SD = 22.6). The AgNOR count was also higher in MM with plasmablasts in the bone marrow (p < 0.001). In addition, the localization of AgNOR changed according to the type of MM: in 84% of mature and intermediate MM NORs were present in the central nucleus whereas in immature and plasmablastic MM NORs were dispersed or near the membrane. Elevated PCNA expression and AgNOR counts was also seen in MM patients with hyperviscosity coma as well as in patients with renal failure. CONCLUSION: PCNA expression and AgNOR count in myeloma indicates the myeloma's proliferative activity and correlates positively with the cytomorphology of plasma cells and clinical outcome.

Adult↗

p21CDKN1A does not interfere with loading of PCNA at DNA replication sites, but inhibits subsequent binding of DNA polymerase delta at the G1/S phase transition.

The ability of the cyclin-dependent kinase (CDK) inhibitor p21CDKN1A to interact with PCNA recruited to DNA replication sites was investigated to elucidate the relevance of this interaction in cell cycle arrest. To this end, expression of p21 protein fused to green fluorescent protein (GFP) was induced in HeLa cells. G1 phase cell cycle arrest induced by p21GFP occurred also at the G1/S transition, as shown by cyclin A immunostaining of GFP-positive cells. Confocal microscopy analysis and co-immunoprecipitation studies showed that p21GFP co-localized and interacted with chromatin-bound PCNA and CDK2. GFP-p21 mutant forms unable to bind to PCNA (p21PCNA-) or CDK (p21CDK-) induced cell cycle arrest, although immunoprecipitation experiments showed these mutants to be unstable. Expression of HA-tagged p21wt or mutant proteins confirmed the ability of both mutants to arrest cell cycle. p21(wt)HA and p21CDK-HA, but not p21PCNA-, co-localized and co-immunoprecipitated with chromatin-bound PCNA. Association of p21 to chromatin-bound PCNA resulted in the loss of interaction with the p125 catalytic subunit of DNA polymerase delta (pol delta). These results suggest that in vivo p21 does not interfere with loading of PCNA at DNA replication sites, but prevents, or displaces subsequent binding of pol delta to PCNA at the G1/S phase transition.

CDC2-CDC28 Kinases↗

[Significance of proliferating cell nuclear antigen (PCNA) index and microvessel density (MVD) in endometrial carcinoma].

BACKGROUND & OBJECTIVE: Incidence of endometrial carcinoma (EC) is ascending, but its pathogenesis and prognosis are unclear. This study was designed to investigate correlation of proliferating cell nuclear antigen (PCNA) index, and microvessel density (MVD) to pathologic stage, and differentiation of endometrial carcinoma. METHODS: PCNA index and MVD in 62 specimens of endometrial carcinoma, and 22 specimens of normal endometrium were detected by SP immunohistochemistry. Correlation of PCNA index, and MVD to pathologic stage, and differentiation of endometrial carcinoma was statistically analyzed. RESULTS: PCNA index, and MVD in endometrial carcinoma were significantly higher than those in normal endometrium (54.5+/-9.3 vs. 32.7+/-7.7, and 49.0+/-8.6 vs. 32.4+/-11.0,P<0.05). PCNA index and MVD positively correlated with pathologic stage and differentiation of endometrial carcinoma (P<0.05). PCNA index positively correlated with MVD in endometrial carcinoma. CONCLUSIONS: The increase of PCNA index and MVD may enhance development of endometrial carcinoma. Angiogenesis might play a role in promoting cell proliferation.

Adenocarcinoma↗

[Analysis of PCNA, Ki67, AgNOR and p53 expression in brain glial tumors].

BACKGROUND AND PURPOSE: The aim of this study was to evaluate clinical usefulness of proliferating cell nuclear antigen (PCNA), Ki67 antigen, p53 protein and silver-binding nucleolar organizer regions (AgNOR) in brain glial tumors. MATERIAL AND METHODS: The investigation of PCNA, Ki67 and p53 was carried out on a group of 120 patients with glial tumors operated on at the Neurosurgical Department of Wroclaw Medical University including 63 patients operated again because of recurrence. AgNOR was evaluated on a group of 64 patients including 38 patients operated again. Classical histological tests, immunohistochemical tests for PCNA, p53 and Ki67 activity with monoclonal antibodies (DACO) and histochemical tests for AgNOR were performed on every specimen of tumor tissue. The level of 40% for PCNA, 2.75 (equal to median) for AgNOR and 5% for Ki67 and p53 was adopted as significant. RESULTS: Mean expression of PCNA of glial tumors grade I and II was 32%, grade III and IV - 44% (p<0.05). Mean expression of AgNOR was 1.88 and 3.16 (p=0.00001), respectively. Average PCNA expression in recurrent tumors to 12 months was 52.7% and for later recurrences - 35.4% (p<0.05). Average expressions of AgNOR were 3.38 and 2.68 (p<0.05), respectively. Differences of Ki67 and p53 expressions were not significant. CONCLUSIONS: PCNA and AgNOR expressions correlate with proliferative activity, growth rate and histological malignancy, reaching high values in highly malignant and early recurrent tumors. Antigens Ki67 and p53 do not seem to be predictive markers of glial tumors.

Adolescent↗

Signs of normal proliferation in the telencephalon of adult male songbirds (serinus serinus), as shown by PCNA-positivity.

The immunocytochemical expression of Proliferating Cell Nuclear Antigen (PCNA) (a cycline that coadjuvates DNA polymerase delta) becomes appreciable in the cell cycle when DNA synthesis occurs; hence cells in the S phase can be revealed by means of monoclonal antibodies. Therefore, PCNA can be considered a marker of proliferation, and numerous literature reports have demonstrated the reliability of the PCNA test. Since normal neurogenic events can still occur in the brain tissue of adult homeothermic vertebrates (especially songbirds), we evaluated if the persistence of spontaneous proliferation could be revealed in adult male songbirds (Serinus serinus) using the PCNA marker, the same test we used previously to study the persistence of natural proliferation in the encephalon of adult heterothermic vertebrates. The patterns of PCNA positivity showed normal proliferation in the telencephalon of the adult male Serinus serinus. This activity was shown by cells interposed among the epithelial cells lining the lateral side of each ventricular cavity, both in correspondence to the apical tracts and declivities of the ependyma and arranged, here and there, either in groups or slightly separated. As in our previous studies on PCNA expression and persistence of spontaneous encephalic proliferation in adult poikilothermal vertebrates (in the telencephalon of Podarcis, Triturus and Rana, and in the telencephalon, mesencephalon and cerebellum of Carassius), the results of the present research largely agree with the findings of previous Authors, usually obtained with different methods. This agreement confirms the reliability of the PCNA test used for this type of investigation.

Animals↗

PCNA-LII, Ki-67 immunostaining, p53 activity and histopathological variables in predicting the clinical outcome in patients with parathyroid carcinoma.

Parathyroid carcinoma is uncommon and no reliable histological markers are available for predicting the clinical outcome of patients. The aim of this study was to assess the correlation between survival, histopatological markers, proliferating cell nuclear antigen (PCNA), Ki-67 antigen and the expression of the p53 nuclear protein in patients with confirmed parathyroid carcinoma (PC). The routine histological specimens from 15 patients (11 men, 4-women, median age 65 years) with confirmed PC who had died of the disease were reviewed. New specimens were also stained with the streptavidin-biotin-peroxidase complex standard technique. The labelling index (LI) of PCNA was quantified by counting 1000 cells from multiple areas in a random fashion, while immunostaining of both Ki-67 and p53 was evaluated as the percentage of positive cells. The PCNA-LI, Ki-67 (%) and p53 (%) values were 14.9 +/- 4.1 (median 13, range 2-70), 13.9 +/- 3.9 (median 11%, range 3-65%) and 38.5 +/- 4.6 (median 29%, range 19-65%), respectively. There was an inverse correlation between age of the patients and p53 (R = -0.73, p = 0.002), but no correlation with both PCNA-LI (R = 0.07, p = 0.72) and Ki-67 (R = -0.07, p = 0.79). A significant relationship (R = 0.93, p < 0.01) between PCNA-LI and Ki-67 was found, while p53 did not correlate with either PCNA-LI (R = -0.11, p = 0.71) or Ki-67 (R = -0.05, p = 0.86). An inverse correlation (R = -0.63, p = 0.01) between survival and the presence of spindle cells and coagulation necrosis together in the standard slides was observed, but there was no correlation (p = NS) between survival and PCNA-LI (R = 0.05), Ki -67 (R = 0.05) or p53 (R = 0.25). In conclusion, none of the tested immunohistochemical markers were useful in predicting the clinical outcome of patients with PC. However, the presence of spindle cells and coagulation necrosis together in the standard specimens should be considered as a negative prognostic factor.

Adult↗